2019's new medicines

January 22, 2020

With 48 drugs approved by the U.S. Food and Drug Administration (FDA), 2019 was another highly productive year for the pharmaceutical industry. The new medicines include treatments for various cancers, sickle cell disease, migraines and postpartum depression. However, the steady flow of drugs could be masking troubling signs about the health of the industry, according to Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society. 

2019 showed several notable trends for new drugs, according to Senior Correspondent Lisa M. Jarvis. First, about 42% of the medicines had new mechanisms of action -- so-called "first-in-class drugs" -- to treat a disease. As in past years, most of FDA's approvals were for small-molecule drugs, but 2019 also saw an influx of new molecular entities, including antibody-drug conjugates, an antisense oligonucleotide and a small interfering RNA. Another trend was the introduction of new therapies for underserved diseases, such as sickle cell anemia, treatment-resistant tuberculosis and postpartum depression.

Despite these successes, some analysts say certain aspects of the list point to trouble ahead for the pharmaceutical industry. For example, the proportion of new drugs produced by big pharma is declining. One explanation is that the industry has shifted its focus from primary-care treatments, which require large, expensive clinical trials, to rare diseases and specialty care indications, like cancer. These classes of drugs can be approved on the basis of much smaller studies, making it easier for small companies to bring a drug to market. Another concerning trend is that the number of companies directly contributing to drug development is shrinking, as large companies acquire the most productive small and medium biotech firms. Analysts worry that this industry consolidation will threaten the ability to introduce new medicines.
The article is freely available here.

For more research news, journalists and public information officers are encouraged to apply for complimentary press registration for the ACS Spring 2020 National Meeting & Exposition in Philadelphia.

The American Chemical Society (ACS) is a nonprofit organization chartered by the U.S. Congress. ACS' mission is to advance the broader chemistry enterprise and its practitioners for the benefit of Earth and its people. The Society is a global leader in providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, eBooks and weekly news periodical Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a specialist in scientific information solutions (including SciFinder® and STN®), its CAS division powers global research, discovery and innovation. ACS' main offices are in Washington, D.C., and Columbus, Ohio.

To automatically receive news releases from the American Chemical Society, contact newsroom@acs.org.

Follow us on Twitter | Facebook

American Chemical Society

Related Postpartum Depression Articles from Brightsurf:

Postpartum depression may persist three years after giving birth
A National Institutes of Health study of 5,000 women has found that approximately 1 in 4 experienced high levels of depressive symptoms at some point in the three years after giving birth.

Researchers zero in on genetic connection to postpartum hemorrhage
Researchers have identified genetic mutations that appear to protect women from severe bleeding after childbirth, a leading cause of maternal death.

Social media can identify fathers at risk of postpartum depression
Fathers' social media posts were evaluated for changes in behavior (engagement with the platform), emotions, linguistic style, and discussion topics following the birth of their child.

Almost half of all postpartum psychosis are isolated cases
A new research result from iPSYCH shows that 40% of the women who suffer a psychosis after giving birth -- known as postpartum psychosis - do not subsequently become ill again.

General anesthesia in cesarean deliveries increases odds of postpartum depression by 54 percent
A new study shows that having general anesthesia in a cesarean delivery is linked with significantly increased odds of severe postpartum depression requiring hospitalization, thoughts of suicide or self-inflicted injury.

Homicide among pregnant, postpartum women in Louisiana
Researchers examined how often homicide was the cause of death among women in Louisiana who were pregnant or up to one year postpartum compared with other causes.

Postpartum women are getting prescribed more opioids than needed
New University of Minnesota Medical School research finds postpartum women are generally getting prescribed more narcotics than they need.

Study teases out factors associated with postpartum overdose
A new study in the journal Addiction that uncovers several risk factors associated with postpartum opioid overdose.

Study suggests a new way to think about the brain's link to postpartum depression
Chronic stress during pregnancy triggers an immune response in the brain that has potential to alter brain functions in ways that could contribute to postpartum depression, new research in animals suggests.

Postpartum depression: For impoverished mothers of color, it takes a community
Treating postpartum depression (PPD) in low-income mothers of color requires an understanding of each person's lived experience, and practitioners should consider interventions that develop broadly from a community level in order to improve outcomes for their clients, according to a University at Buffalo social work researcher.

Read More: Postpartum Depression News and Postpartum Depression Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.